Neuropathic pain affects millions of people, including chemotherapy patients, people with diabetes, and patients suffering from peripheral nerve damage.
Dr. Peter Goldstein, professor of anesthesiology, was featured in Weill Cornell Medicine’s Daedalus Fund for Innovation Progress Report, for his research to develop a new, non-opioid treatment for this debilitating type of chronic pain.
“We have identified a lead compound that holds the promise of introducing a new approach to treating neuropathic pain,” said Dr. Goldstein, whose research is supported by Weill Cornell Medicine’s Daedalus Fund for Innovation.
Launched in 2014, the Daedalus Fund is designed to advance early- stage applied and translational research projects that have significant commercial potential.
Read more about Dr. Goldstein's research in the report, below:
Daedalus_Fund_Momentum_in_Action.pdf
Related Information
- Dr. Peter Goldstein's research profile
- The Daedalus Fund at Weill Cornell Medicine